Thomas D. Salus - 14 Apr 2025 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Role
Chief Legal & Administration
Signature
/s/ Rebecca Hilt, Attorney-In-Fact for Thomas D Salus
Issuer symbol
LFCR
Transactions as of
14 Apr 2025
Net transactions value
$0
Form type
4
Filing time
16 Apr 2025, 16:38:47 UTC
Next filing
10 Jul 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LFCR Common Stock Award +45,000 45,000 14 Apr 2025 Direct F1
transaction LFCR Common Stock Award +170,000 +378% 215,000 14 Apr 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LFCR Performance-Based Restricted Stock Units Award $0 +370,000 $0.000000 0 14 Apr 2025 Common Stock 370,000 Direct F2, F3, F4
transaction LFCR Incentive Stock Option (Right to Buy) Award $0 +210,000 $0.000000 210,000 14 Apr 2025 Common Stock 210,000 $6.17 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2 Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3 Represents the maximum number of performance-based restricted stock units that can vest based on the Issuer's achievement of certain stock price milestones.
F4 The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock prices.